A phase 3 clinical trial published in JAMA found trastuzumab rezetecan linked to 73% lower risk of cancer progression or death versus chemotherapy.
A phase 3 clinical trial published in JAMA found trastuzumab rezetecan linked to 73% lower risk of cancer progression or death versus chemotherapy.
End of DispatchRead Original Coverage on foxnews